Colorectal Cancer Clinical Trials in Austin, TX

Colorectal Cancer Clinical Trials in Austin, TX

View the best 10 colorectal cancer medical studies in Austin, Texas. Access promising new therapies by applying to a Austin-based Colorectal Cancer clinical trial.

Trials in Austin, Texas

Here are the top 10 medical studies for colorectal cancer in Austin, Texas

Image of Moffitt Cancer Center in Tampa, United States.

KPT-8602

XPO1 inhibitor

Recruiting1 awardPhase 1 & 2
This trial will assess the safety, tolerability, and preliminary efficacy of KPT-8602, an oral XPO1 inhibitor, in patients with relapsed/refractory multiple myeloma, metastatic colorectal cancer, metastatic castration resistant prostate cancer, higher risk myelodysplastic syndrome, acute myeloid leukemia, and newly diagnosed intermediate/high-risk MDS.
Image of Los Angeles County-USC Medical Center in Los Angeles, United States.

Ceralasertib +1 More

Enzyme Inhibitor

Recruiting1 awardPhase 1
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Image of START Midwest in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug called NGM831 alone or with other drugs in patients with advanced or spreading solid tumors. The goal is to see if these treatments can help stop the cancer or help the immune system fight it better. One of the drugs being tested has been widely studied and used in various cancers, showing significant improvements in survival rates and being effective in combination with other treatments.
Image of START Midwest, LLC in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Image of NEXT Oncology in San Antonio, United States.

CBX-12

Chemotherapy

Recruiting1 awardPhase 1 & 2
This trial tests a new drug called CBX-12 on patients with advanced tumors that haven't responded to other treatments. The goal is to find the safest and most effective dose by trying different schedules.
Image of University Of Alabama At Birmingham in Birmingham, United States.

Nivolumab +1 More

Checkpoint Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing a combination of drugs to treat patients with advanced colon or rectal cancer who have already tried other treatments. The drugs help the immune system fight cancer and block proteins that help cancer grow. One of the drugs being tested has shown promise in treating advanced colorectal cancer.
Image of Dignity Health St Joseph's Hospital and Medical Center in Phoenix, United States.

Entrectinib

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 2
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Image of Carta - Clinical Associates in Research Therapeutics of America, LLC in San Antonio, United States.

Ponsegromab +1 More

Monoclonal Antibodies

Recruiting0 awardsPhase 2
This trial tests Ponsegromab, a new drug, on cancer patients who are losing weight and have high GDF 15 levels. The drug aims to lower GDF 15 to improve appetite and reduce weight loss.
Image of Exelixis Clinical Site #6 in Duarte, United States.

XL092

Recruiting1 awardPhase 1
This trial is testing a new drug called XL092 by itself and with two other drugs, atezolizumab and avelumab. It targets patients with advanced solid tumors who may not respond to current treatments. XL092 aims to stop cancer cells from growing, while atezolizumab and avelumab help the immune system fight the cancer. Atezolizumab is approved for various cancers, including breast and urothelial carcinoma, and has shown efficacy in combination with chemotherapy.
Image of Astera Cancer Center in East Brunswick, United States.

Tislelizumab +3 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial will compare the standard of care for second line treatment of metastatic colorectal cancer (mCRC) against different combinations of NIS793 and other investigational drugs. The goal is to see if this new approach is more effective and has fewer side effects.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.